Empagliflozin and linagliptin and Seconal Sodium

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Secobarbital may reduce the blood levels of linagliptin, which may make the medication less effective in treating your condition. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need to monitor your blood sugar more closely during treatment with these medications, and also for a week or two after you discontinue secobarbital. Let your doctor know if your condition changes or you experience loss of blood sugar control while you are using these medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

GENERALLY AVOID: Coadministration with potent inducers of the CYP450 3A4 isoenzyme and/or P-glycoprotein efflux transporter may significantly decrease the plasma concentrations of linagliptin, which is a substrate for both. The interaction may produce subtherapeutic and likely ineffective plasma concentrations of linagliptin. According to the product labeling, coadministration of linagliptin (5 mg orally once daily) with the potent CYP450 3A4/P-glycoprotein inducer rifampin (600 mg once daily) to steady state resulted in decreases to linagliptin peak plasma concentration (Cmax) by 44% and systemic exposure (AUC) by 40% compared to administration alone.

MANAGEMENT: Due to the potential for reduced efficacy of linagliptin, coadministration with potent CYP450 3A4 and/or P-glycoprotein inducers such as carbamazepine, dexamethasone, enzalutamide, phenobarbital, phenytoin, rifamycins, and St. John's wort should generally be avoided. For patients requiring use of such drugs, an alternative to linagliptin is strongly recommended. Other known inducers of CYP450 3A4 include aminoglutethimide, barbiturates, bexarotene, bosentan, dabrafenib, efavirenz, modafinil, nafcillin, nevirapine, and various other anticonvulsants, although the extent to which they interact with linagliptin is unknown. If concomitant use with these agents is necessary, glycemic control should be closely monitored.

Empagliflozin and linagliptin

Generic Name: empagliflozin / linagliptin

Brand name: Glyxambi

Synonyms: Empagliflozin and Linagliptin

What is Empagliflozin and linagliptin?

Seconal Sodium

Generic Name: secobarbital

Brand name: Seconal Sodium, Seconal

Synonyms: n.a.

What is Seconal Sodium?